These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 25551831)

  • 1. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.
    Bradley JS; Puttagunta S; Rubino CM; Blumer JL; Dunne M; Sullivan JE
    Pediatr Infect Dis J; 2015 Jul; 34(7):748-52. PubMed ID: 25551831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.
    Scoble PJ; Owens RC; Puttagunta S; Yen M; Dunne MW
    Clin Drug Investig; 2015 Dec; 35(12):785-93. PubMed ID: 26458939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.
    Gonzalez D; Bradley JS; Blumer J; Yogev R; Watt KM; James LP; Palazzi DL; Bhatt-Mehta V; Sullivan JE; Zhang L; Murphy J; Ussery XT; Puttagunta S; Dunne MW; Cohen-Wolkowiez M
    Pediatr Infect Dis J; 2017 Jul; 36(7):645-653. PubMed ID: 28060045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly dalbavancin versus daily conventional therapy for skin infection.
    Boucher HW; Wilcox M; Talbot GH; Puttagunta S; Das AF; Dunne MW
    N Engl J Med; 2014 Jun; 370(23):2169-79. PubMed ID: 24897082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.
    Billeter M; Zervos MJ; Chen AY; Dalovisio JR; Kurukularatne C
    Clin Infect Dis; 2008 Feb; 46(4):577-83. PubMed ID: 18199045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
    Dunne MW; Puttagunta S; Sprenger CR; Rubino C; Van Wart S; Baldassarre J
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1849-55. PubMed ID: 25561338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
    Kim A; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
    Marbury T; Dowell JA; Seltzer E; Buckwalter M
    J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
    Das B; Sarkar C; Biswas R; Pandey S
    Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.
    Dunne MW; Zhou M; Darpo B
    Int J Antimicrob Agents; 2015 Apr; 45(4):393-8. PubMed ID: 25681068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
    Van Matre ET; Teitelbaum I; Kiser TH
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dalbavancin on the normal intestinal microflora.
    Nord CE; Rasmanis G; Wahlund E
    J Antimicrob Chemother; 2006 Sep; 58(3):627-31. PubMed ID: 16840427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.